Adaptive Biotechnologies Corporation is a biotechnology company listed on the Nasdaq under the ticker symbol ADPT. The company’s mission is to translate the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases. On Tuesday, April 2, 2024, after the market closes at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, Adaptive Biotechnologies will be hosting a business update conference call and webcast. The live audio of the webcast will be available on the “Investors” section of the company website at www.adaptivebiotech.com. The webcast will also be archived for replay within 24 hours after the event.
Adaptive Biotechnologies is dedicated to harnessing the biology of the adaptive immune system to revolutionize disease diagnosis and treatment. The company believes that this powerful tool has not been fully utilized due to challenges in decoding it, but its immune medicine platform enables rapid and precise decoding of its genetics with scale. Through collaboration with biopharmaceutical companies, drug development informs, and clinical diagnostics are developed in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. These products and pipeline aim to aid in diagnosing, monitoring, and treating diseases such as cancer, autoimmune disorders, and infectious diseases with personalized immune-driven clinical products for each patient as their ultimate goal.
For investors looking for more information or guidance, Karina Calzadilla can be reached at investors@adaptivebiotech
